Hacettepe University, Faculty of Pharmacy, Department of Radiopharmacy, 06100, Sihhiye, Ankara, Turkey; Izmir Katip Celebi University, Faculty of Pharmacy, Department of Radiopharmacy, 35620, Cigli, Izmir, Turkey.
Hacettepe University, Faculty of Pharmacy, Department of Radiopharmacy, 06100, Sihhiye, Ankara, Turkey.
Crit Rev Ther Drug Carrier Syst. 2020;37(5):435-471. doi: 10.1615/CritRevTherDrugCarrierSyst.2020031657.
Globally, lung cancer is one of the most frequently diagnosed and deadliest types of cancer. Lung cancer imaging can be performed using both invasive and noninvasive techniques, including magnetic resonance, positron emission tomography, single photon emission computed tomography, chest radiography, and computed tomography. But nonspecific contrast agents and radiopharmaceuticals are insufficient for early and specific diagnoses and imaging. In the case of lung cancer therapy, conventional therapeutic agents and radiotherapy may cause severe and systemic adverse and toxic effects and fail to eradicate all tumor tissue. Therefore, formulation of novel, targeted, and specific agents is critically important to overcome these challenges. In this review, we summarize lung cancer classification, current methods for lung cancer imaging and therapy, and future options containing nanosized systems for lung cancer imaging and/or therapy.
在全球范围内，肺癌是最常见和最致命的癌症之一。肺癌的影像学检查可以采用有创和无创技术，包括磁共振成像、正电子发射断层扫描、单光子发射计算机断层扫描、胸部 X 射线摄影和计算机断层扫描。但是，非特异性造影剂和放射性药物不足以进行早期和特异性诊断和成像。在肺癌治疗方面，传统的治疗剂和放疗可能会引起严重的全身性不良反应和毒性作用，而且无法彻底清除所有肿瘤组织。因此，开发新型的、靶向的、特异性的制剂对于克服这些挑战至关重要。在这篇综述中，我们总结了肺癌的分类、目前的肺癌成像和治疗方法，以及未来包含纳米系统的肺癌成像和/或治疗的选择。
